文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

早产儿视网膜病变活动度量表及临床试验结局指标的开发

Development of a Retinopathy of Prematurity Activity Scale and Clinical Outcome Measures for Use in Clinical Trials.
PubMed 文献 · JAMA Ophthalmol · 2019-01-01

国际新生儿联盟召集药企、从业者、监管机构、资助机构、科学家及家庭等利益相关方,针对早产儿视网膜病变(ROP)临床试验需要客观标准化结局指标以满足监管要求的问题,提出开发更新的ROP急性病变活动度与结构量表及不同年龄段的终末期结构与眼科结局指标。该量表基于当前诊断方法与治疗,拟作为临床干预试验的指南,并计划通过回顾性数据验证及迭代修订。

要点

  • 现有ROP国际分类未涵盖ROP全部特征,且不能充分区分治疗后微小变化。
  • 需开发更新的ROP急性活动度与结构量表及不同年龄段的终末期结构与眼科结局指标。
  • 量表应动态修订并利用记录良好的临床试验数据验证,以提升试验数据质量。

核心结论

  • 需要ROP活动度量表及结局指标以获取临床试验中最稳健和具区分度的数据。

研究设计与样本

  • 国际新生儿联盟汇集药企、从业者、监管机构、资助机构、科学家及家庭等利益相关方形成共识性观察。

主要发现

  • 当前ROP国际分类未考虑ROP全部特征且不能充分区分治疗后微小变化。
  • 需要更新的ROP急性疾病活动度与结构量表及不同年龄段的终末期结构与眼科结局指标。
  • 量表基于当前诊断方法与治疗,可作为临床干预试验的指南,并拟通过回顾性数据验证及迭代修订。

临床怎么用

  • 该量表与结局指标可用于临床干预试验的指南,并通过迭代修订纳入新措施以评估预后价值。

局限性

  • 量表尚需回顾性数据验证并修订后方可用于未来试验;需在知识和成像模式进步后动态修改并利用记录良好的临床试验数据验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: To facilitate drug and device development for neonates, the International Neonatal Consortium brings together key stakeholders, including pharmaceutical companies, practitioners, regulators, funding agencies, scientists, and families, to address the need for objective, standardized clinical trial outcome measurements to fulfill regulatory requirements. Retinopathy of prematurity (ROP) is a disease that affects preterm neonates. The current International Classification of Retinopathy of Prematurity does not take into account all of the characteristics of ROP and does not adequately discriminate small changes in disease after treatment. These factors are critical for evaluating outcomes in clinical trials. OBSERVATIONS: There is need for an updated ROP acute disease activity and structure scale as well as end-stage structure and ophthalmologic outcome measures designed for use at different ages. The scale and measures, based on current diagnostic methods and treatments, could be used as a guideline for clinical intervention trials. The scale is intended to be validated against retrospective data and revised for use in future trials. An iterative revision process can be accomplished if new measures are added to clinical trials and evaluated at the end of each trial for prognostic value. The new measures would then be incorporated into a new version of the activity scale and the outcome measures revised. CONCLUSIONS AND RELEVANCE: An ROP activity scale and outcome measures to obtain the most robust and discriminatory data for clinical trials are needed. The scales should be dynamic and modified as knowledge and imaging modalities improve and then validated using data from well-documented clinical trials. This approach is relevant to improving clinical trial data quality.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Smith LEH, Hellström A, Stahl A, et al. Development of a Retinopathy of Prematurity Activity Scale and Clinical Outcome Measures for Use in Clinical Trials. JAMA Ophthalmol. 2019. PMID: 30543348. doi:10.1001/jamaophthalmol.2018.5984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。